Our work on optimal treatment in presence of cancer persisters is out today in @prxlife.bsky.social 🎉
Alternated drug-release periods may be an advantage due to dose-dependent transition rates and slow death of persisters
journals.aps.org/prxlife/abst...
journals.aps.org
Extending persistence modeling to drug-induced, dose-dependent cancer persistence reveals that strategic drug holidays and reduced doses can improve long-term treatment outcomes.